The Approved & Available RNA-Based Vaccine by Merck Animal Health On November 1, 2023 a significant announcement came from Merck Animal Health: their RNA-based Sequevity vaccine, designed to target H1N1, H1N2, and H3N2 influenza strains through the influenza neuraminidase surface antigen, has hit the commercial market.
Understanding mRNA Vaccines mRNA vaccines operate by instructing cells to produce a protein that prompts an immune response, teaching the body to recognize and fight the disease without exposing it to the disease itself.
Health Implications The introduction of mRNA vaccines in livestock holds many unknowns, especially regarding the long-term health effects of consuming meat from vaccinated animals.
Consumers are right to be cautious, given the historical precedents of unforeseen health consequences in RNA vaccine innovations.
The emergence of mRNA vaccine use in livestock, coupled with a lack of mandatory clear labeling or disclosure, magnifies existing apprehensions regarding the provenance and handling of the meat we consume.
In an era where consumers are increasingly demanding to know more about their food's provenance and production, the industry's move towards more opaque technological interventions, like the mRNA vaccine, feels like a step backward.
Sometimes even more time is needed for newer technologies, which mRNA vaccines would qualify as for sure.
No comments:
Post a Comment